The company, founded in 2015 and based in Woburn, Massachusetts, is a clinical-stage biotechnology company that uses its Progenitor Cell Activation approach to create functional tissue by activating progenitor cells within the body through combinations of molecules. Its lead product candidate FX-322 is being developed to treat sensorineural hearing loss. Frequency Therapeutics aims to restore human function by developing therapeutics that activate a person's innate regenerative potential within the body, with a focus on driving remyelination and potential functional recovery for individuals living with multiple sclerosis.